Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human Malignancies
- 1 June 2002
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (11) , 2616-2623
- https://doi.org/10.1200/jco.2002.22.030
Abstract
PURPOSE: Capecitabine and docetaxel have demonstrated preclinical antitumor synergy. This synergy is thought to occur from docetaxel-mediated upregulation of thymidine phosphorylase (dThdPase), an ...Keywords
This publication has 17 references indexed in Scilit:
- Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II TrialJournal of Clinical Oncology, 2001
- Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2001
- A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patientsAnnals of Oncology, 2001
- Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients.Oncology Reports, 2000
- A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumoursBritish Journal of Cancer, 2000
- Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemotherapy and Pharmacology, 2000
- Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2000
- Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 1999
- 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.Proceedings of the National Academy of Sciences, 1993
- Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5?-deoxy-5-fluorouridineCancer Chemotherapy and Pharmacology, 1993